Patents by Inventor Tomas Norling
Tomas Norling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140179731Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.Type: ApplicationFiled: December 26, 2013Publication date: June 26, 2014Applicant: Veloxis Pharmaceuticals A/SInventors: Robert D. Gordon, Per Holm, Anne-Marie Lademann, Tomas Norling
-
Patent number: 8685998Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.Type: GrantFiled: July 7, 2009Date of Patent: April 1, 2014Assignee: Veloxis Pharmaceuticals A/SInventors: Robert D. Gordon, Per Holm, Anne-Marie Lademann, Tomas Norling
-
Publication number: 20140073665Abstract: A modified release composition comprising tacrolimus which is useful for the treatment or prevention of rejection reactions by transplantation of organs or tissues.Type: ApplicationFiled: November 13, 2013Publication date: March 13, 2014Applicant: Veloxis Pharmaceuticals A/SInventors: Per HOLM, Tomas Norling
-
Publication number: 20140066473Abstract: A modified release composition comprising tacrolimus which is useful for the treatment or prevention of rejection reactions by transplantation of organs or tissues.Type: ApplicationFiled: November 13, 2013Publication date: March 6, 2014Applicant: Veloxis Pharmaceuticals A/SInventors: Per HOLM, Tomas NORLING
-
Publication number: 20140065225Abstract: A modified release composition comprising tacrolimus releases less than 20% w/w of the active ingredient within 0.5 hours when subjected to an in vitro dissolution test using USP Paddle method and using 0.1 N HCl as dissolution medium and has increased bioavailability by effectively reducing or even avoiding the effects of CYP3A4 metabolism. The modified composition may be coated with an enteric coating; and/or may comprise a solid dispersion or a solid solution of tacrolimus in a hydrophilic or water-miscible vehicle and one or more modifying release agents; and/or may comprise a solid dispersion or a solid solution of tacrolimus in an amphiphilic or hydrophobic vehicle and optionally one or more modifying release agents.Type: ApplicationFiled: November 13, 2013Publication date: March 6, 2014Applicant: Veloxis Pharmaceuticals A/SInventors: Per HOLM, Tomas Norling
-
Patent number: 8664239Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.Type: GrantFiled: June 23, 2011Date of Patent: March 4, 2014Assignee: Veloxis Pharmaceuticals A/SInventors: Robert D. Gordon, Per Holm, Anne-Marie Lademann, Tomas Norling
-
Patent number: 8623410Abstract: A modified release composition comprising tacrolimus releases less than 20% w/w of the active ingredient within 0.5 hours when subjected to an in vitro dissolution test using USP Paddle method and using 0.1 N HCl as dissolution medium and has increased bioavailability by effectively reducing or even avoiding the effects of CYP3A4 metabolism. The modified composition may be coated with an enteric coating; and/or may comprise a solid dispersion or a solid solution of tacrolimus in a hydrophilic or water-miscible vehicle and one or more modifying release agents; and/or may comprise a solid dispersion or a solid solution of tacrolimus in an amphiphilic or hydrophobic vehicle and optionally one or more modifying release agents.Type: GrantFiled: June 23, 2011Date of Patent: January 7, 2014Assignee: Veloxis Pharmaceuticals A/SInventors: Per Holm, Tomas Norling
-
Patent number: 8623411Abstract: A modified release composition comprising tacrolimus releases less than 20% w/w of the active ingredient within 0.5 hours when subjected to an in vitro dissolution test using USP Paddle method and using 0.1 N HCl as dissolution medium and has increased bioavailability by effectively reducing or even avoiding the effects of CYP3A4 metabolism. The modified composition may be coated with an enteric coating; and/or may comprise a solid dispersion or a solid solution of tacrolimus in a hydrophilic or water-miscible vehicle and one or more modifying release agents; and/or may comprise a solid dispersion or a solid solution of tacrolimus in an amphiphilic or hydrophobic vehicle and optionally one or more modifying release agents.Type: GrantFiled: June 23, 2011Date of Patent: January 7, 2014Assignee: Veloxis Pharmaceuticals A/SInventors: Per Holm, Tomas Norling
-
Patent number: 8617599Abstract: A modified release composition comprising tacrolimus releases less than 20% w/w of the active ingredient within 0.5 hours when subjected to an in vitro dissolution test using USP Paddle method and using 0.1 N HCl as dissolution medium and has increased bioavailability by effectively reducing or even avoiding the effects of CYP3A4 metabolism. The modified composition may be coated with an enteric coating; and/or may comprise a solid dispersion or a solid solution of tacrolimus in a hydrophilic or water-miscible vehicle and one or more modifying release agents; and/or may comprise a solid dispersion or a solid solution of tacrolimus in an amphiphilic or hydrophobic vehicle and optionally one or more modifying release agents.Type: GrantFiled: June 23, 2011Date of Patent: December 31, 2013Assignee: Veloxis Pharmaceuticals A/SInventors: Per Holm, Tomas Norling
-
Patent number: 8586084Abstract: A modified release composition comprising tacrolimus releases less than 20% w/w of the active ingredient within 0.5 hours when subjected to an in vitro dissolution test using USP Paddle method and using 0.1 N HCl as dissolution medium and has increased bioavailability by effectively reducing or even avoiding the effects of CYP3A4 metabolism. The modified composition may be coated with an enteric coating; and/or may comprise a solid dispersion or a solid solution of tacrolimus in a hydrophilic or water-miscible vehicle and one or more modifying release agents; and/or may comprise a solid dispersion or a solid solution of tacrolimus in an amphiphilic or hydrophobic vehicle and optionally one or more modifying release agents.Type: GrantFiled: June 23, 2011Date of Patent: November 19, 2013Assignee: Veloxis Pharmaceuticals A/SInventors: Per Holm, Tomas Norling
-
Publication number: 20130303612Abstract: The invention provides stable, solid dosage forms and pharmaceutical compositions in particulate form comprising a fibrate, for example fenofibrate, dissolved in a non-aqueous vehicle in order to ensure improved bioavailability of the active ingredient upon oral administration relative to known fibrate formulations.Type: ApplicationFiled: February 25, 2013Publication date: November 14, 2013Applicant: Veloxis Pharmaceuticals A/SInventors: Per Holm, Tomas Norling
-
Patent number: 8582444Abstract: The present invention provides a method of detecting a faulty network element in a network, the network comprising at least a plurality of first network elements having a first network element type, and at least a plurality of second network elements having a second network element type.Type: GrantFiled: August 28, 2008Date of Patent: November 12, 2013Assignee: Telefonaktiebolaget L M Ericsson (publ)Inventors: Oscar Zee, Tomas Norling
-
Patent number: 8481078Abstract: The invention provides stable, solid dosage forms and pharmaceutical compositions in particulate form comprising a fibrate, for example fenofibrate, dissolved in an non-aqueous vehicle in order to ensure improved bioavailability of the active ingredient upon oral administration relative to known fibrate formulations.Type: GrantFiled: December 8, 2011Date of Patent: July 9, 2013Assignee: Veloxis Pharmaceuticals A/SInventors: Per Holm, Tomas Norling
-
Publication number: 20120195965Abstract: The invention provides stable, solid dosage forms and pharmaceutical compositions in particulate form comprising a fibrate, for example fenofibrate, dissolved in an non-aqueous vehicle in order to ensure improved bioavailability of the active ingredient upon oral administration relative to known fibrate formulations.Type: ApplicationFiled: December 8, 2011Publication date: August 2, 2012Applicant: Veloxis Pharmaceuticals A/SInventors: Per HOLM, Tomas NORLING
-
Patent number: 8124125Abstract: The invention provides stable, solid dosage forms and pharmaceutical compositions in particulate form comprising a fibrate, for example fenofibrate, dissolved in an non-aqueous vehicle in order to ensure improved bioavailability of the active ingredient upon oral administration relative to known fibrate formulations.Type: GrantFiled: December 18, 2009Date of Patent: February 28, 2012Assignee: Veloxis Pharmaceuticals A/SInventors: Per Holm, Tomas Norling
-
Publication number: 20120029009Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.Type: ApplicationFiled: June 23, 2011Publication date: February 2, 2012Applicant: LifeCycle Pharma A/SInventors: Robert D. Gordon, Per Holm, Anne-Marie Lademann, Tomas Norling
-
Publication number: 20110275659Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.Type: ApplicationFiled: June 23, 2011Publication date: November 10, 2011Applicant: LifeCycle Pharma A/SInventors: Robert D. GORDON, Per HOLM, Anne-Marie LADEMANN, Tomas NORLING
-
Publication number: 20110263632Abstract: A pharmaceutical composition comprising tacrolimus (FK-506) dissolved and/or dispersed in a hydrophilic or water-miscible vehicle to form a solid dispersion or solid solution at ambient temperature have improved bioavailability.Type: ApplicationFiled: July 7, 2011Publication date: October 27, 2011Applicant: Veloxis Pharmaceuticals A/SInventors: Per HOLM, Tomas Norling
-
Publication number: 20110256190Abstract: A modified release composition comprising tacrolimus releases less than 20% w/w of the active ingredient within 0.5 hours when subjected to an in vitro dissolution test using USP Paddle method and using 0.1 N HCl as dissolution medium and has increased bioavailability by effectively reducing or even avoiding the effects of CYP3A4 metabolism. The modified composition may be coated with an enteric coating; and/or may comprise a solid dispersion or a solid solution of tacrolimus in a hydrophilic or water-miscible vehicle and one or more modifying release agents; and/or may comprise a solid dispersion or a solid solution of tacrolimus in an amphiphilic or hydrophobic vehicle and optionally one or more modifying release agents.Type: ApplicationFiled: June 23, 2011Publication date: October 20, 2011Applicant: LifeCycle Pharma A/SInventors: Per HOLM, Tomas Norling
-
Publication number: 20110250277Abstract: A modified release composition comprising tacrolimus releases less than 20% w/w of the active ingredient within 0.5 hours when subjected to an in vitro dissolution test using USP Paddle method and using 0.1 N HCl as dissolution medium and has increased bioavailability by effectively reducing or even avoiding the effects of CYP3A4 metabolism. The modified composition may be coated with an enteric coating; and/or may comprise a solid dispersion or a solid solution of tacrolimus in a hydrophilic or water-miscible vehicle and one or more modifying release agents; and/or may comprise a solid dispersion or a solid solution of tacrolimus in an amphiphilic or hydrophobic vehicle and optionally one or more modifying release agents.Type: ApplicationFiled: June 23, 2011Publication date: October 13, 2011Applicant: LifeCycle Pharma A/SInventors: Per Holm, Tomas Norling